Dr Mascarenhas on the Use of Selinexor in Myelofibrosis

John Mascarenhas, MD, discusses the use of selinexor with ruxolitinib in JAK inhibitor–naive myelofibrosis, highlighting the phase 2 XPORT-MF-044 trial

Related Keywords

John Mascarenhas ,Tisch Cancer Institute ,Icahn School Of Medicine ,Icahn School ,Mount Sinai ,Blood Cancers ,Myeloid Disorders ,Onclive Tv ,Reviewing Research Efforts Seeking To Raise The Bar In Myelofibrosis ,